Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Losartan (Primary) ; Rosuvastatin (Primary)
  • Indications Dyslipidaemias; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Hanmi Pharmaceutical

    • Most Recent Events

    • 14 Nov 2017 Primary endpoint (Change from baseline in sitDBP in the A/L/R 5/100/20 mg and L/R 100/20 mg groups)has been met as per the results published in the Clinical Therapeutics
    • 14 Nov 2017 Primary endpoint (Percentage change from baseline in LDL-cholesterol in the A/L/R 5/100/20 mg group and A/L 5/100 mg group) has been met as per the results published in the Clinical Therapeutics
    • 14 Nov 2017 Results published in the Clinical Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top